A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Clinical trial NCT02610062 · TERMINATED
Trial details
- NCT number
- NCT02610062
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-29
- Primary completion
- 2017-09-22
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.